Global Information
회사소개 | 문의

수막염균 감염증 : 파이프라인 리뷰

Neisseria meningitidis Infections - Pipeline Review, H2 2018

리서치사 Global Markets Direct
발행일 2018년 10월 상품 코드 293895
페이지 정보 영문 87 Pages
가격
US $ 2,000 ₩ 2,278,800 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,557,600 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,836,400 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


수막염균 감염증 : 파이프라인 리뷰 Neisseria meningitidis Infections - Pipeline Review, H2 2018
발행일 : 2018년 10월 페이지 정보 : 영문 87 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

수막염균 감염증은 혈류 및 수막(뇌 및 척수를 싸고 있는 얇은 막)에 세균이 감염되는 중대한 질환으로, 증상은 열, 경부 경직, 관절통, 구토, 의식 장애 등입니다. 위험인자는 연령, 흡연, 점막병변, 인파, 건계·가뭄 등의 기후, 황사, 호흡기질환과의 동시 감염 등을 들 수 있습니다.

세계 각국의 수막염균 감염증(Neisseria Meningitidis Infections) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발·출시 최신 동향, 임상시험 각 단계의 제품 목록, 주요 기업 개요, 주요 치료제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

목차

서론

  • 분석 범위

수막염균 감염증 개요

치료제 개발

  • 수막염균 감염증용 파이프라인 제품 : 개요
  • 기업별 파이프라인 제품
  • 대학/연구기관별 파이프라인 제품
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

수막염균 감염증 치료제 개발 참여 기업

  • Beijing Minhai Biotechnology Co Ltd
  • Biological E Ltd
  • China National Pharmaceutical Group Corp
  • GlaxoSmithKline Plc
  • Griffith University
  • ImmunoBiology Ltd
  • JN-International Medical Corp
  • MGB Biopharma Ltd
  • Panacea Biotec Ltd
  • Pfizer Inc
  • Sanofi Pasteur SA
  • Serum Institute of India Ltd
  • Wellstat Vaccines LLC

약제 개요

수막염균 감염증 치료제 : 개발 휴지 상태인 제품

수막염균 감염증 치료제 : 개발이 중지된 제품

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

LSH 17.06.12

List of Tables

  • Number of Products under Development for Neisseria meningitidis Infections, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Neisseria meningitidis Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2018
  • Neisseria meningitidis Infections - Pipeline by Biological E Ltd, H2 2018
  • Neisseria meningitidis Infections - Pipeline by China National Pharmaceutical Group Corp, H2 2018
  • Neisseria meningitidis Infections - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2018
  • Neisseria meningitidis Infections - Pipeline by GlaxoSmithKline Plc, H2 2018
  • Neisseria meningitidis Infections - Pipeline by Hualan Biological Engineering Inc, H2 2018
  • Neisseria meningitidis Infections - Pipeline by ImmunoBiology Ltd, H2 2018
  • Neisseria meningitidis Infections - Pipeline by Johnson & Johnson, H2 2018
  • Neisseria meningitidis Infections - Pipeline by MGB Biopharma Ltd, H2 2018
  • Neisseria meningitidis Infections - Pipeline by Pfizer Inc, H2 2018
  • Neisseria meningitidis Infections - Pipeline by Sanofi Pasteur SA, H2 2018
  • Neisseria meningitidis Infections - Pipeline by Serum Institute of India Ltd, H2 2018
  • Neisseria meningitidis Infections - Pipeline by Tianjin CanSino Biotechnology Inc, H2 2018
  • Neisseria meningitidis Infections - Pipeline by Wellstat Vaccines LLC, H2 2018
  • Neisseria meningitidis Infections - Dormant Projects, H2 2018
  • Neisseria meningitidis Infections - Dormant Projects, H2 2018 (Contd..1), H2 2018
  • Neisseria meningitidis Infections - Dormant Projects, H2 2018 (Contd..2), H2 2018
  • Neisseria meningitidis Infections - Discontinued Products, H2 2018

List of Figures

  • Number of Products under Development for Neisseria meningitidis Infections, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Targets, H2 2018
  • Number of Products by Stage and Targets, H2 2018
  • Number of Products by Mechanism of Actions, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neisseria meningitidis Infections - Pipeline Review, H2 2018, provides an overview of the Neisseria meningitidis Infections (Infectious Disease) pipeline landscape.

Neisseria Meningitidis is a severe bacterial infection of the bloodstream and meninges (a thin lining covering the brain and spinal cord). Symptoms include fever, neck stiffness, joint pain, nausea, confusion and drowsiness. Risk factors include age, smoking, mucosal lesions, overcrowding, climatic conditions such as dry seasons or prolonged drought and dust storms and concomitant respiratory infections.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neisseria meningitidis Infections - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Neisseria meningitidis Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neisseria meningitidis Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Neisseria meningitidis Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 4, 3, 9, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively.

Neisseria meningitidis Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neisseria meningitidis Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neisseria meningitidis Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neisseria meningitidis Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neisseria meningitidis Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neisseria meningitidis Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Neisseria meningitidis Infections - Overview
    • Neisseria meningitidis Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Neisseria meningitidis Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Neisseria meningitidis Infections - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co Ltd
    • Biological E Ltd
    • China National Pharmaceutical Group Corp
    • Chongqing Zhifei Biological Products Co Ltd
    • GlaxoSmithKline Plc
    • Hualan Biological Engineering Inc
    • ImmunoBiology Ltd
    • Johnson & Johnson
    • MGB Biopharma Ltd
    • Pfizer Inc
    • Sanofi Pasteur SA
    • Serum Institute of India Ltd
    • Tianjin CanSino Biotechnology Inc
    • Wellstat Vaccines LLC
  • Neisseria meningitidis Infections - Drug Profiles
    • (diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (Haemophilus influenzae B + Neisseria meningitidis [serotypes A, C, Y, W135]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MenBioVax - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotype B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotype B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotype B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotype B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotype B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, B, C] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W, Y] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W-135, Y] (quadrivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C, W135, X, Y] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes A, C] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal [serotypes C, Y] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • meningococcal vaccine 1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MGBBP-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCL-195 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Neisseria meningitidis [serotype B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-06886992 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TP-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Neisseria meningitidis Infections - Dormant Projects
  • Neisseria meningitidis Infections - Discontinued Products
  • Neisseria meningitidis Infections - Product Development Milestones
    • Featured News & Press Releases
      • Apr 23, 2018: Pfizer Granted FDA Breakthrough Therapy Designation for TRUMENBA (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Children Ages 1 to 9 Years
      • Mar 06, 2018: TRUMENBA (Meningococcal Group B Vaccine) Now Available In Canada
      • Dec 13, 2017: Phase 3 TRUMENBA (Meningococcal Group B Vaccine) Data Published In New England Journal Of Medicine Demonstrate The Vaccine's Immunogenicity
      • Sep 12, 2017: TGA approves MENVEO vaccine to help protect babies from two months old from meningococcal disease
      • Jul 11, 2017: Recall of MENVEO [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine] Solution for intramuscular injection
      • May 30, 2017: European Commission Approves Pfizer's Trumenba To Help Prevent Meningococcal Group B Disease In Adolescents And Adults
      • Mar 24, 2017: Pfizer Receives Positive CHMP Opinion for TRUMENBA for Prevention of Meningococcal Group B Disease
      • Mar 24, 2017: GSK Announces Availability of Menveo (meningococcal ACWY vaccine)
      • Oct 19, 2016: CDC Advisory Committee on Immunization Practices Votes to Recommend New Dosing Schedule for Vaccination with TRUMENBA (Meningococcal Group B Vaccine)
      • May 20, 2016: Pfizer Announces European Medicines Agency Acceptance For Review Of Marketing Authorization Application For TRUMENBA (Meningococcal Group B Vaccine)
      • May 13, 2016: Pfizer Presents Results From Two Phase 3 TRUMENBA (Meningococcal Group B Vaccine) Studies At The European Society For Pediatric Infectious Diseases Meeting
      • Oct 09, 2015: Pfizer's Phase 2 Study Demonstrates Safety, Tolerability and Immunogenicity of TRUMENBA When Co administered with Meningococcal A, C, Y and W-135 Polysaccharide Conjugate and Tetanus, Diphtheria and Pertussis Vaccines in Adolescents
      • Aug 21, 2015: Pfizer Announces Positive Top line Results Of Two Phase 3 Studies Of TRUMENBA (Meningococcal Group B Vaccine)
      • Jun 24, 2015: CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination including TRUMENBA for Adolescents and Young Adults 16 through 23 Years of Age
      • Feb 26, 2015: CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination for Persons at Increased Risk
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
이용안내
 
BCC Research